Ultragenyx Pharmaceutical (Ultragenyx Pharmaceutical) Interest Expense : $-66.2 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Ultragenyx Pharmaceutical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Ultragenyx Pharmaceutical's interest expense for the three months ended in Mar. 2024 was $ -15.8 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-66.2 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Ultragenyx Pharmaceutical's Operating Income for the three months ended in Mar. 2024 was $ -165.3 Mil. Ultragenyx Pharmaceutical's Interest Expense for the three months ended in Mar. 2024 was $ -15.8 Mil. Ultragenyx Pharmaceutical did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ultragenyx Pharmaceutical Interest Expense Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Interest Expense Chart

Ultragenyx Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-1.14

-33.29

-29.42

-43.02

-66.00

Ultragenyx Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-15.64	-15.38	-17.67	-17.33	-15.85

Ultragenyx Pharmaceutical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.2 Mil.

Ultragenyx Pharmaceutical (NAS:RARE) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ultragenyx Pharmaceutical's Interest Expense for the three months ended in Mar. 2024 was $-15.8 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-165.3 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $28.0 Mil.

Ultragenyx Pharmaceutical's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Ultragenyx Pharmaceutical did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Ultragenyx Pharmaceutical (Ultragenyx Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (NAS:RARE) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

RARE:Mexico UP0:Germany

Address

60 Leveroni Court, Novato, CA, USA, 94949

Website

https://www.ultragenyx.com

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Executives

Emil D Kakkis	director, 10 percent owner, officer: President & CEO	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Thomas Richard Kassberg	officer: CBO & Senior Vice President	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Howard Horn	officer: Chief Financial Officer	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Theodore Alan Huizenga	officer: Controller and PAO	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Erik Harris	officer: EVP & Chief Commercial Officer	60 LEVERONI COURT, NOVATO CA 94949
Sanders Corazon (corsee) D.	director	C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
John Richard Pinion	officer: See Remarks	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Karah Herdman Parschauer	officer: EVP and General Counsel	60 LEVERONI COURT, NOVATO CA 94949
Eric Crombez	officer: EVP and Chief Medical Officer	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Dennis Karl Huang	officer: SVP and Chief Tech Ops Officer	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Camille L Bedrosian	officer: EVP and Chief Medical Officer	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Mardi Dier	officer: CFO & Executive Vice President	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Amrit Ray	director	60 LEVERONI COURT, NOVATO CA 94949
William Aliski	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Shalini Sharp	officer: CFO & Senior Vice President	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949